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1. Introduction 
Glucocorticoids are steroid hormones synthesized in the adrenal gland cortex, and most of 
their physiological effects are mediated by the glucocorticoid receptor (GR), that acts as a 
ligand-dependent transcription factor. Coordinate changes in metabolism under 
glucocorticoid influence provide energy that is instantly and selectively available to vital 
organs, an enables them to deal with immediate environmental demands, at the expense of 
anabolic pathways, such as bone formation, reproduction, immunological responses and 
other, that are being blunted or delayed, under glucocorticoid influence [1-3]. 
During fetal development the synthesis of adrenal glucocorticoids precedes the 
establishment of a definitive structure of the gland. In rats, secretion of the main 
glucocorticoid – corticosterone starts as early as on day 13 of development [4] (term=22 
days, short gestation period), while in humans secretion of the main glucocorticoid – cortisol 
starts in the 8th week of pregnancy (term=40 weeks, long gestation period) [5]. 
Glucocorticoid receptor mRNA is present in the tissue derivatives of all three germ layers 
from fetal day 13 onwards, and increases gradually during rat fetal development [6]. 
Human fetal tissues express GR at the gestational age of 6 weeks, meaning that the 
machinery for hormone action is prepared at the early stages of development [5]. These facts 
suggest that endogenous glucocorticoids produced by the fetal adrenal glands have a crucial 
role in fetal growth and the development of individual fetal tissues [7]. In response to the 
prepartum rise in glucocorticoids a wide variety of changes known as “preparation for 
birth” occurs, meaning that the maturational changes in many fetal tissues, essential for 
neonatal survival, are intensified during the last third of gestation. Namely, circulating 
glucocorticoids induce fetal lung maturation and surfactant production, trigger a variety of 
physiological effects on brain cell differentiation and synaptogenesis, stimulate the 
production of hepatic gluconeogenic enzymes, affect pancreatic -cell development and 
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insulin content, influence renal development and affect the maturation of the immune 
system [8-10]. Metabolic, cardiovascular and immune adaptations under glucocorticoid 
influence are fundamental to successfully overcoming birth-related stress and postnatal 
adaptation of the newborn to environmental challenges [11, 12].    
Environmental conditions influence the prevailing nutritional and endocrine status in 
mothers and fetuses. Numerous animal and human studies have shown that adverse 
environmental conditions during pregnancy, such as maternal undernutrition [13, 14], stress 
[15, 16], illness, placental insufficiency [17, 18], as well as prenatal glucocorticoid exposure 
[19, 20] affect fetal development and postnatal outcome. Changes in the maternal 
hypothalamic-pituitary-adrenal (HPA) activity, transplacental diffusion of nutrients, 
hormones and growth factor supply, potently affect the fetal HPA axis influencing 
glucocorticoid output as well as other developing systems [21, 22]. Gestational age, at which 
an insult occurs, its nature and intensity, determines the specific tissue or organ which will 
be affected by the insult. Glucocorticoids are the key mediators between maternal 
environment and the fetus, and as such are involved in adaptations of the fetus to predicted 
postnatal environment. Even transient changes in glucocorticoid levels could have long-
lasting consequences. The outcome might be growth retardation and change in the 
developmental trajectory, in the direction that best suited to the expected environment [23, 
24]. This phenomenon is known as programming. The adaptations caused by suboptimal 
intrauterine conditions are appropriate if the predicted and actual postnatal environments 
match, and lead to survival to reproduce in a deprived environment [25, 26]. If there is a 
mismatch between the environment predicted and the actual environment experienced 
postnatally, adaptations are inappropriate and result in the development of disease like 
hypertension, ischemic heart disease, glucose intolerance, insulin resistance and type 2 
diabetes [27-29].  
In this chapter the latest findings, with clear statements from the literature, as well as own 
results regarding the endocrine mechanisms of intrauterine programming mediated by 
glucocorticoids will be analyzed. The causal relationship between a prenatally programmed 
endocrine axes and their postnatal functioning that affect growth, stress response, 
metabolism and reproduction will be discussed. In order to better understand mechanisms 
of fetal glucocorticoid programming of endocrine axes, special attention will be paid to key 
points of their development.   
2. Development of endocrine axses 
2.1. Development of hipothalamic-pituitary-adrenal axis 
Functional differentiation of anterior pituitary cells is under the control of transcription 
factors and their cofactors. The transcription factors expressed in early pituitary 
development such as Rpx/Hesx1, Ptx1, Ptx2, Lhx3 regulate the formation of Rathke’s pouch 
and maintain the formation of the baseline cellular structure. Signaling between the 
developing hypothalamus and the Rathe's pouch is also involved in the initial formation of 
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pituitary primordia and further differentiation of the pituitary gland. Hypothalamic BMP 4 
and FGF 8 are required for the activation of expression and maintenance of expression of the 
early transcriptional factors in the pouch. The lineage of adrenocorticotropin (ACTH) 
producing cells arises first during organogenesis, and thus represents a separate lineage. 
Pituitary homeobox 1 (Ptx1/Pitx1) was reported as factor for differentiation towards 
proopiomelanocortin (POMC) cells [30]. In the fetal pituitary the first cells that are 
immunopositive for ACTH can be found on fetal day 13 in the pars tuberalis anlage, 
whereas ACTH immunostaining is found 1 day later in the pars distalis [31]. The pars 
intermedia of the fetal rat pituitary is the last part to display ACTH staining [32]. Although 
pituitary precursor cells are influenced by spatial cues and extrinsic signals, for the initiation 
of ACTH synthesis in the fetal pituitary, a certain degree of autonomy exists. Moreover, 
ACTH immunostaining was found in 11-day-old fetal rat pituitary primordia cultured for 4 
days in a serum-free medium, thus without endocrine or neuroendocrine signals [33]. 
Furthermore, ACTH-containing cells were detected in anencephalic human fetuses [34].  
In the next stage of differentiation of ACTH-producing cells, the hypothalamic 
(corticotropin-releasing hormone) CRH control over ACTH cells has an indispensable 
role. In rats, the appearance of hypothalamic CRH-containing neurons occurs in lateral 
hypothalamic areas and in the paraventricular nucleus (PVN) on days 15.5 and 16.5 of 
gestation, respectively, whereas beaded fibers are visible in the external layer of the 
median eminence on day 17.5 of gestation [35]. Expression of CRH is correlated with a 
progressive rise in ACTH in the fetal circulation. A progressive 10-fold increase in ACTH 
concentration occurs in the pars distalis on days 17–20 of gestation [36], which suggests a 
crucial role of the developing hypothalamus. From the 20th day of gestation until term, the 
ACTH concentration remains unchanged. The existence of a mechanism that overcomes 
the negative feedback effect of elevated glucocorticoid levels on POMC gene expression 
during late pregnancy was demonstrated [37]. From that period onwards, ACTH is stored 
in the fetal pituitary gland as a readily releasable pool. Its location near the fenestrated 
capillary network enables momentary depletion of significant amounts of ACTH, and a 
subsequent considerable increase in ACTH concentration in the circulation, if 
physiologically demanded [38].  
The cells of the adrenal cortex arise early in development due to the local proliferation of 
cells from the splanchnic mesoderm. The genes coding the orphan nuclear receptors SF-1 
and DAX-1 control the early fetal adrenal cortex development. Knockout mice for these 
genes manifest adrenal and gonadal agenesis, gonadotropin deficiency and the absence of 
the hypothalamic ventromedial nucleus [39]. The potential for steroid synthesis occurs early, 
in 12-day-old rat fetuses [40]. In the later stages of fetal life, ACTH controls growth and 
development, as well as steroidogenic maturation of the adrenal glands [41]. Histological 
analysis of a near term rat fetal adrenal glands showed that the main part of the gland is 
steroidogenic tissue composed of a zona glomerulosa (ZG) and an inner zone (IZ), while the 
number of migrating chromoblasts is still modest [42]. Both cortical zones are functionally 
competent and able to produce aldosterone and corticosterone in 19-day-old fetuses [43]. 
The proliferative activity of adrenocortical cells is most intensive in the outer portion of the 
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glands, in the subcapsular ZG region and outer portion of IZ from where the cells migrated 
centripetally [44]. A balance between proliferation and cell death enables proper functioning 
and integrity of the developing adrenal glands. Programmed cell death appears to occur in 
the inner cortical layers, where many resident macrophages are present [4], as well as in the 
resorption zones and giant cells [45, 46].  
The development of the human adrenal glands exhibits a number of important differences 
in histological organization and steroidogenic activity in relation to species with a short-
term gestation period. The primordium of the human fetal adrenal glands can be recognized 
by 3–4 weeks of gestation, but by the 8th week of embryonic development the adrenal cortex 
is clearly identifiable with its characteristic zonal partitioning [47]. The principal steroids of 
primate fetal adrenal gland, i.e. fetal zone situated in the inner part of the gland, are 
dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS). DHEA serves as a substrate 
for placental estrone and estradiol production. Rapid growth of the fetal adrenal cortex, 
especially the fetal zone, with a significant increase in steroidogenic activity begins after 
week 10 of gestation and continues until term [47]. The definitive zone, positioned at the 
peripheral part of the gland, is steroidogenically inert, at last until the second trimester of 
pregnancy. After this period mineralocorticoid production were found, although 
aldosterone synthesis in the fetal adrenals is in poor correlation with plasma rennin activity. 
The transitional zone that becomes distinguishable between fetal and definitive zone at the 
end of the second trimester of pregnancy represents a precursor of the adult zona fasciculata 
(ZF). The expression of enzymes 3β hydroxysteroid dehydrogenase (3βHSD) and 
cytochrome P450 17α-hydroxylase/lyase (CYP17) in the transitional zone enables the 
capacity for cortisol production [48]. In the initial phase, the fetal adrenals begin to produce 
cortisol between weeks 10 and 20 of gestation, possibly utilizing progesterone as a 
precursor. However, de novo synthesis of cortisol from cholesterol is established fairly late in 
gestation, leading to a remarkable increase in cortisol concentrations in the third trimester. 
Immediately after birth, the fetal zone of the adrenal cortex degenerates extensively, 
whereas the ZF matures in the subsequent period. [48]. Although the presence of ACTH is 
established in circulation from week 15 of gestation, cortisol and androgen production by 
the definitive and fetal zone are maximally stimulated by circulating ACTH from 
midgestation [49].  
The functional state of the fetal HPA axis is important for several reasons. Firstly, 
glucocorticoids play a role in the maturation of numerous organs necessary for intrauterine 
development and extrauterine existence. Organ systems involved in reaching metabolic 
homeostasis, stress response and electrolyte balance in outer space are strongly controlled 
by glucocorticoids [50]. Secondly, the fetal HPA negative feedback mechanism begins to 
operate between days 15 and 17 of rat gestation [51]. Thus, near term fetuses are able to 
regulate their own homeostasis and glucocorticoid production in response to different 
maternal stressors [52] and adverse conditions [37]. Finally, the fetal HPA axis activity 
strongly affects the timing of parturition [48]. In a number of species at the end of gestation 
there is an increase in HPA activity, with increased plasma glucocorticoid levels that reflects 
on the placental trophoblast cells, causing enhanced output of prostaglandins [37]. The 
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effects of prostaglandins on the myometrium associated with increased oxytocin activity 
represent an important step in the initiation of birth [50].   
2.1.1. Effects of glucocorticoids during fetal development  
Strictly defined spatial and temporal effects of glucocorticoids are actually determined by 
the previous appearance of the GR. In situ hybridization histochemistry revealed GR gene 
expression in the tissue derivatives of all three germ layers. The facts that intense GR mRNA 
labeling happened just before the final differentional step for each glucocorticoid target 
tissue, and that upon differentiation reduced amounts of GR mRNA were found further 
support the crucial morphogenic role of glucocorticoids during fetal development [6].   
Sufficient glucocorticoid levels are essential for the normal maturation of many parts of CNS 
during the prenatal period. In general, glucocorticoids act on neuronal maturation, 
replication, differentiation, and programmed cell death [8, 12]. In parallel with reducing the 
rate of neuronal replication, glucocorticoids promote the differentiation of central 
noradrenergic, serotonergic and dopaminergic neurons, enhance axonal growth, dendritic 
arborisation and synaptogenesis in a regionally selective manner, and control programmed 
cell death [53, 54].  
Glucocorticoids promote the differentiation of sympathoadrenal precursors, initially 
expressed multiple neuronal markers, into endocrine chromaffin cells in the adrenal gland 
medulla. As sympathoadrenal precursors invade the primordium of the fetal adrenal gland 
and migrate centripetally, they are exposed to adrenal steroids. The initial adrenaline 
synthesis occurs in parallel with a sharp rise in the adrenal tissue and plasma glucocorticoid 
concentrations, and the appearance of GR in the sympathoadrenal precursor cells in 17-day-
old rat fetuses [55]. Thus, glucocorticoids represent an important signal for the induction 
and maintenance of adrenaline synthesis in the adrenal medulla, but initial induction of the 
adrenaline-synthesizing enzyme, phenylethanolamine-N-methyltransferase is rather 
determined by a cell-intrinsic timed process in the chromaffin precursors [56]. 
Glucocorticoids accelerate lung maturation as they speed up the thinning of the double 
capillary loop to form the thin gas exchanging walls of the alveoli. By enhancing the 
production of surfactant by type II pneumocytes, glucocorticoids allow the newborn to 
draw its first breath and enable the start of the breathing process [57].  
In the fetal liver, glucocorticoids promote the activity of the key gluconeogenic enzyme 
systems and hepatic glycogen deposition in preparation for the nutritional transition at 
birth. Inability of the adrenalectomised sheep fetuses to induce glucogenesis during extreme 
circumstances such as maternal undernutrition with reductions in hepatic glycogen content 
was associated with lower circulating concentrations of cortisol [10]. It might be concluded 
that birth-related stress and subsequent environmental challenges trigger glucocorticoid 
actions essentially involved in the activation of fetal glucogenesis and glucose availability 
necessary for maintaining homeostasis after birth. 
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By combining in vitro studies with in vivo investigations in mice lacking the GR in the whole 
organism or in specific pancreatic cell populations, it has been shown that glucocorticoids 
are important hormones in pancreatic development. Acting before insulin expression onset, 
glucocorticoids decreased the differentiation of the embryonic pancreas into β-cells favoring 
acinar cells differentiation. Deletion of the GR in pancreatic precursor cells led to increased 
β-cell mass. Thus, glucocorticoids unable β-cells mass expansion in later stages, by 
modifying the balance of specific transcription factors, mostly Pdx-1 [9]. At birth, as the 
placental source of glucose is lost, tight glycemic control must be established. A prepartum 
rise in glucocorticoid levels in fetal horse and sheep increases pancreatic β cells sensitivity to 
glucose and influences the fetal insulin level, enabling active regulation of the glucose level 
after birth, and thus the transition to enteral supply [10, 22].  
The highest expression of the GR mRNA was identified during early kidney development in 
the developing glomeruli, epithelial cells of the proximal and distal renal tubule, and the 
central collecting duct. Reduction of GR levels in the fully differentiated glomeruli pointed 
out the importance of glucocorticoids during a defined period of establishment of the 
definitive renal structure and function [5].  
Effective thermoregulation in response to cold exposure in the extrauterine environment 
post birth is crucial to prevent hypothermia in newborns. The expression of mitochondrial 
uncoupling protein (UCP), that catalyzes adaptive thermogenesis in mammalian brown 
adipose tissue increases dramatically during the final week of gestation in fetal adipose 
tissue [58]. The late-gestation augment in fetal plasma glucocorticoid levels as well as 
application of synthetic glucocorticoids enhance mitochondrial UCP expression, suggesting 
that glucocorticoids are crucially involved in increasing the thermogenic potential of fetal 
adipose tissue near term [59, 60].  
2.2. Development of the somatotropic axis 
Growth hormone (GH) is secreted from the anterior pituitary gland under the control of 
two hypothalamic hormones: the releasing hormone is growth hormone-releasing 
hormone (GHRH), and the release-inhibiting hormone is somatostatin (SRIH). In addition 
to these two neurohormones, a number of factors such as free fatty acids, acetylcholine, 
amino acids, opiates, glucocorticoids and some neuropeptides also have direct or indirect 
effects on GH release. Most of the metabolic actions of GH are mediated by insulin-like 
growth factor I (IGF-I), which is produced in many different tissues, with most of the 
circulating IGF-I being derived from the liver. IGF-I has anabolic as well as metabolic 
effects in many cell types, acting through autocrine, paracrine and classical endocrine 
mechanisms. IGF signaling has been recognized as one of the major molecular regulators 
of cell growth and proliferation [61]. Moreover, it is generally accepted that GH, by 
controlling important aspects of IGF activity in many tissues and cell types of mammals, 
is able to coordinate somatic growth in a defined spatio-temporal manner at the whole 
body level [62]. IGF signaling, however, not only regulates growth but also affects 
differentiation and may, through epigenetic processes, steer adult cell function as a result 
of particular conditions during postnatal development [63]. 
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In rat, GHRH neurons are detected at the 16th day of fetal development [64], while SRIH 
mRNA in the periventricular nucleus of the hypothalamus is expressed on the 14th fetal 
day [65]. Initial pituitary GH expression is detected on day 15 of gestation using sensitive 
methods such as the reverse transcriptase-polymerase chain reaction (RT-PCR) [66]. In the 
following phase of GH cell development the expression of Pit-1 occurs. Pit-1 is a pituitary-
specific transcriptional factor that mediates cell proliferation and differentiation into 
specific hormone-producing cell types – thyrotropes, somatotropes or lactotropes [67]. 
During this period, the quantity of GH transcripts remains at an extremely low level. A 
marked increase in cell number and GH production occurs between days 18 and 19 of 
fetal development [68]. The expression of the GHRH receptor also occurs on fetal day 19 
in rats [69, 70]. 
It has been considered that pituitary GH promotes and controls fetal development  
and body weight by stimulating the family of hepatic growth factors. Recent 
investigations showed that extrapituitary GH as well as local production of growth factors 
had great paracrine/autocrine influence on fetal developmental processes and 
differentiation. The expression of GH and GH receptor in a wide variety of tissues is 
established before the pituitary gland and circulatory system become functional [71].  
In rats and mice a contribution of the pituitary GH to growth, development and body 
weight has been demonstrated postnatally, during the second week of life [72]. The 
influence of pituitary GH on normal growth and body weight in near-term fetuses, 
immediately after the GH cells become functional, is still difficult to understand and not 
well defined. 
In humans, GH cells are evident at 8 weeks of gestation, with abundant immunoreactive 
cytoplasmic GH expression. Plasma GH concentrations are highest at midgestation and 
thereafter fall until term. The pattern of ontogenesis of plasma GH reflects the progressive 
maturation of hypothalamic–pituitary and forebrain function. The responses of GH to SRIH 
and GHRH are mature at term in human infants [73].   
IGF-1 and IGF-2 mRNA transcripts are present in virtually all fetal tissues [74]. Both IGFs 
are also detected in the fetal circulation from early gestation, but the plasma concentrations 
of IGF-II are 3–10 fold higher than those of IGF-I during late gestation [75]. They are present 
in serum and other extracellular fluids associated with highly specific binding proteins (IGF 
binding proteins (IGFBPs)). In the fetus, IGFs are predominantly complexed with IGFBP-1 
and -2, and the liver is the predominant production site for these IGFBPs [76]. Tissue and 
plasma IGF-II are higher in the fetus than in newborn or adult animals in most species [77]. 
In rodents, IGF-II expression disappears from most tissues except the brain by weaning, 
with the consequence that IGF-II is virtually undetectable in adult plasma [78]. In contrast, 
plasma IGF-I levels increase rapidly after birth, primarily as a result of the onset of GH 
stimulated IGF-I production by the liver [79], since IGF regulation is GH-independent 
during the fetal period [74]. There is, therefore, a shift in IGF predominance from IGF-II 
before birth to IGF-I after birth, which has led to the concept that IGF-II is the IGF primarily 
responsible for fetal growth [80].  
 Glucocorticoids – New Recognition of Our Familiar Friend 344 
2.3. Development of hypothalamic-pituitary-thyroid axis 
The development of thyroid-stimulating hormone (TSH) cells in the fetal rat pituitary pars 
distalis is determined by the expression of Pit-1 and TEF transcription factors [67]. 
Differentiation from precursor cells enables detection of TSH cells mRNA on day 15 of 
gestation [81], while immunocytochemically recognized TSH cells can be observed in 16.5- 
to 17.5-day-old fetuses. TSH cells were few in 17.5-day-old rat fetuses, but their number 
increased thereafter, particularly during the 2nd week after birth [68].   
In the rat fetal hypothalamus, thyrotropin-releasing hormone (TRH), which promotes 
prompt synthesis and secretion of anterior pituitary TSH, is first detected on the 16th day of 
gestation [82]. The destruction of paraventricular nuclei (PVN), which contain TRH 
neuronal cell bodies, results in a significant decrease in anterior pituitary TSHβ- and α-
subunit mRNA levels, as well as in serum TSH concentrations [83]. During the fetal period a 
major influence of TSH is to control the morphological and functional maturation of the fetal 
thyroid gland.      
The thyroid gland is derived from the fusion of a medial outpouching from the floor of the 
primitive pharynx and bilateral evaginations of the fourth pharyngeal pouch, giving rise to 
the precursors of follicular (thyroxine-producing cells) and parafollicular (calcitonin-
producing C cells) cells. Coordinate action of numerous transcription factors is involved in 
thyroid morphogenesis. Titf1, Hhex, Pax8 and Foxe1 are expressed in the rat just prior to the 
first appearance of the thyroid diverticulum on fetal day 9.5–10, controlling the 
proliferation, survival and migration of precursor cells [84]. Targeted disruption of Titf1 in 
mice results in total absence of the thyroid tissue, while the lack of Pax8 results in follicle 
agenesis, with the remaining tissue being composed almost exclusively of C-cells [85, 86].  
In rats on fetal day 17 significant growth and rapid functional and structural development 
of the thyroid gland are established. The first appearance of follicles, iodine organification 
and thyroid hormonogenesis occur in parallel with a marked increase of TSH in fetal 
circulation and the expression of TSH receptors (TSHR) in thyroid tissue. Thus, 
upregulation of TSHR gene expression by TSH in fetuses is crucial for further maturation of 
the thyroid [81].    
Deiodinase enzymes provide biologically active triiodothyronine (T3) to developing tissues 
by activating and/or deactivating systemic serum thyroid hormones (TH). Three types of 
iodothyronine deiodinases (D1, D2, D3) have been identified, which differ in tissue 
distribution, substrate specificity and sensitivity to inhibiting compounds [87].  Expression 
of D1 is low through gestation, while D2 and D3 are the major isoforms in the fetus [88]. D2 
is the activating enzyme that catalyzes the removal of one iodide from the outer tyrosine 
ring of thyroxine (T4) and production of active T3. D3 is the inactivating enzyme that 
catalyzes the cleaving of one iodide from the inner tyrosine rings of T4 or T3, thus 
generating reverse T3 (rT3) or T2. Action of D2 and D3 preserves the safe level of T3 in the 
developing brain and the pituitary [87], while the activity of D3 in the utero-placental unit 
protects fetal tissues against high maternal T4 concentrations. Local tissue deiodinase 
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activity is essential for compensation and adaption to potential malfunctions in the fetal 
hypothalamic-pituitary-thyroid (HPT) axis, i.e. in the case of congenital hypothyroidism and 
normal maternal T4, the transfer of the latter, together with increased brain D2 activity, 
protects the fetal brain from T3 deficiency [89]. 
In humans, thyroid gland reaches maturity by the 11th–12th week of gestation, when tiny 
follicle precursors with thyroglobulin in follicular space can be seen and iodine binding is 
detected. In this period both T4 and T3 are measurable in fetal serum [90]. At this stage of 
early development maternal T4 transplacental passage contributes to the fetal hormonal 
status, which is essential for normal early fetal neurogenesis. In the later stages of 
development, if fetal thyroid function is normal, placental TH passage is relatively limited 
due to the presence of D3 [91]. The increase in total T4 and free T4 levels between weeks 18 
and 36 of gestation indicates maturation of the HPT axis function, with the establishment of 
feedback control about midgestation.  
2.4. Development of the endocrine pancreas   
The embryogenesis of pancreas is mediated by a series of transcription factors involved in 
morphogenesis. The expression of Pdx1 has been found early in organ formation, in cells that 
give rise to endocrine and exocrine cells of the mouse neonatal pancreas. In Pdx1 null mice 
pancreas agenesis occurs. The appearance of insulin and glucose transporter GLUT2 is also 
regulated by this transcription factor [92]. Transcription factors Hlxb9 and Isl1 are necessary 
for the initial induction of Pdx1. Hlxb9 is observed during the formation of pancreatic anlage 
and later during the differentiation of β cells. Neurogenin 3 has been identified as the key 
regulator of endocrine development, giving rise to all pancreatic endocrine lineages [93].  
The pancreas arises from a multipotent endodermal cell population that will produce ductal, 
exocrine and endocrine cells [94]. The human fetal pancreas develops during the 5th week of 
gestation, while endocrine cells are identifiable by the 8th or 9th week of gestation. Scattered 
single endocrine cells are recognized to produce insulin (β-cell), glucagon (α-cells), 
somatostatin (δ-cells) and pancreatic polypeptide (PP cells). Clusters of epithelial endocrine 
cells form primitive islets of Langerhans a few weeks later, in parallel with the expression of 
neural adhesion molecule (N-CAM) [95]. The largest expansion of the β-cell mass has been 
shown to take place in the second half of prenatal development, from approximately 20 
weeks in humans. This developmental period is critical to achieve a β-cell mass required to 
ensure proper insulin secretion throughout life. It is thought to result from β-cell neogenesis 
from rapidly dividing undifferentiated progenitor cells [96]. Thereafter, some degree of β-
cell expansion persists at least until adolescence due to β-cell neogenesis, mitosis and 
perhaps to transdifferentiation of α-cells, acinar or ductal cells [97].   
During the development of insulin-expressing cells there is a changing phenotype, from 
progenitor cells to immature β-cells, and finally, to mature adult β-cells. Using gene 
expression and immunohistochemistry, differences among late-embryonic, neonatal, and 
adult β-cells were found in a series of markers with transient expression patterns during the 
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perinatal period. Of these, cytokeratin-19, matrix metalloproteinase-2 and surfactant 
protein-D can be considered as true markers of new and immature β-cells, as their 
expression is transient and not entirely synchronous, but absent in adults [98]. Sympathetic 
innervation and vascularization of islets play important roles in normal islet morphogenesis 
during prenatal life, and have trophic effects on β-cells survival, maturation and insulin 
secretion [99].   
Human and rodent fetal islets are insensitive to glucose, as fetal β-cells do not discriminate 
between different glucose levels, despite adequate insulin reserves. Relative functional 
immaturity in utero was also recorded in response to circulating amino acids, particularly 
leucine, catecholamines and neural stimulation, with regard to the capacity to secrete both 
insulin and glucagon [100]. For blunted capacity for insulin and glucagon secretion several 
causes are proposed. Firstly, during fetal development in mammals glucose homeostasis is 
mainly achieved by the mother because of a constant supply of glucose by placental transfer 
through facilitated diffusion. Secondly, the mechanisms that mediate insulin secretion in 
adults are immature in fetuses, meaning that the production of cAMP is decreased, 
expression of glucose transporter GLUT2 is lower and expression of voltage-gated L-type 
Ca2+ channels is diminished in β-cells [100, 101]. Furthermore, generalized immaturity of the 
metabolic enzyme expression in pancreatic β-cells during the fetal and neonatal period in 
the rat has been recorded. Lower expression levels of the metabolic enzyme genes such as 
malate dehydrogenase, glycerol-3-phosphate dehydrogenase, glutamate oxaloacetate 
transaminase and pyruvate carboxylase were established and confirmed by quantitative 
PCR during fetal development and several weeks after birth than in adults [102]. During 
fetal life GH might be involved in the process of β-cell mass expansion and maturation that 
finally leads to an effective response to hyperglycaemia [103].   
2.5. Development of the hypothalamic-pituitary-gonadal axis 
Reproductive physiology in mammals is centrally regulated through the hypothalamic–
pituitary–gonadal (HPG) axis and depends on gonadotropin-releasing hormone (GnRH). 
GnRH, a decapeptide, is released into the hypophyseal portal vasculature from axon 
terminals at the median eminence and binds to the GnRH receptor (GnRHR), which is 
specifically expressed in gonadotrope cells in the anterior pituitary gland. GnRH signaling 
controls the biosynthesis and release of luteinizing hormone (LH) and follicle-stimulating 
hormone (FSH), which in turn regulate the development and activity of the ovaries and 
testes. LH and FSH, together with TSH, are heterodimeric glycoproteins composed of a 
common α-subunit (αGSU) and a hormone-specific β-subunit (LHβ, FSHβ).  
The crucial maturation events at the hypothalamic–pituitary level are the onset of GnRH 
synthesis, access of GnRH to the hypothalamic–hypophysial circulation, appearance of 
GnRH receptors in the pituitary gonadotropes, and the onset of gonadotropin synthesis and 
secretion. Traces of GnRH in whole rat brain extracts were detected as early as on day 12 of 
gestation, and by the 17th day of gestation immunoreactive GnRH cells within the brain were 
distributed in a pattern similar to that of the adult, projecting neurosecretory axons to the 
median eminence [104].  
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Although gonadotrope is the last cell type in the anterior pituitary to reach maturation with 
the expression of terminal differentiation markers LHβ, FSHβ, and GnRHR, αGSU is the 
first pituitary hormone transcript expressed during development. In mice, it is first detected 
at fetal day 10.5 in the most ventral region of Rathke’s pouch [105]. Gonadotrope specific 
expression of αGSU is regulated by SF1, which plays essential roles at multiple levels of the 
reproductive axis, reviewed in [106]. However, no single transcription factor has been 
demonstrated to be necessary and sufficient for gonadotrope lineage commitment [107]. In 
the rat pituitary, on fetal day 16 rare LHβ were detected by in situ hybridization. Many more 
cells hybridizing LHβ and FSHβ were observed on day 17. At this stage, the fetal pituitary 
gland becomes GnRH responsive [104]. Recently, it has been shown that two types of 
gonadotropes may become responsive to GnRH at different time points during 
development [108].  
In humans, fetal pituitary gonadotropins are secreted as early as at 12 weeks of gestation. 
Marked rises in the pituitary and plasma concentrations of FSH and LH are observed during 
the second trimester of gestation, and significantly higher levels of circulating 
gonadotropins are detected in female than in male fetuses [109]. 
Gonad development is a unique system in which a single rudimentary tissue can be induced 
to form one of two different organs, the ovary or the testis. The gonads originate from the 
thickening of the ventrolateral epithelium along the embryonic mesonephros surface, called 
the genital ridge, and in mice are visible at fetal day 10. Proliferation of these epithelial cells 
gives rise to somatic cells of the gonad. By contrast, the germ cell lineage arises outside the 
urogenital ridge before the formation of gonads. Mouse primordial germ cells (PGCs) are 
specified in the epiblast, and are first detected at about fetal day 7.25 using alkaline 
phosphatase as a marker [110]. PGCs proliferate and migrate through the gut mesentery into 
the urogenital ridge, populating the gonads between the 10th and 11th day of fetal 
development. The exact trigger that initiates PGCs migration to the genital ridge and the 
chemoattractants that are required for the directional movement toward the genital ridge 
are slowly beginning to be understood [111]. 
In mammals, the choice between the male or the female gonad, is initiated by a single gene 
on the Y chromosome, Sry (sex-determining region of the Y chromosome). Sry is expressed 
in the somatic cells of the XY gonad between 10.5 and 12.0 of gestation [112] and encodes a 
putative transcription factor that acts as a genetic switch for male development. The Sry 
protein is expressed in each pre-Sertoli cell during a narrow window of several hours in the 
period of gonadal differentiation, between fetal days 10.5 and 12.5, resulting in up-
regulation of Sox9, the major gene transcriptionally downstream of Sry [113]. If Sry is 
expressed in the rudimentary gonad, either from the Y chromosome or from an ectopic 
transgene, a testis forms [114]. If Sry is not expressed, as in XX individuals or in cases where 
Sry is mutated or deleted, an ovary forms [115]. Based on this, it was believed that the 
presence of Sry actively caused testis development to occur, and that in the absence of Sry 
the ovary developed passively (i.e. the so-called “default” pathway). Recent discoveries 
have now made it clear that early ovarian development is an active process that involves the 
interaction and competition of multiple signaling pathways that specify male or female 
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development. The two alternative sex fates are thought to emerge through the antagonistic 
activities of sex-specific transcription factors in a restricted number of gonadal cells. This 
initial cell fate decision is further expanded by extracellular non-cell-autonomous signals 
that promote one developmental program, while at the same time suppressing the other 
[116]. Studies have identified two secreted factors, Wnt4 and follistatin, which are required 
during early gonad development to repress the aspects of testis differentiation in XX 
gonads, reviewed in [111]. 
By fetal day 13.5, germ cells in XX and XY gonads have taken different developmental  
paths. In XY gonads germ cells undergo mitotic arrest as prospermatogonia, whereas in  
XX gonads the germ cells enter the prophase of the first meiotic division. The fate of  
germ cells is dependent on the somatic environment, and not on the chromosomal sex  
of the germ cells [117]. Thus, signals from adjacent somatic cells must direct the 
differentiation of germ cells in the embryonic gonads, although these signals have not been 
identified. 
The onset of gonadal endocrine activity is very clearly sexually dimorphic. During 
embryogenesis, male differentiation requires the secretion of three testicular hormones. 
Anti-Müllerian hormone (AMH), produced by fetal Sertoli cells, induces regression of the 
Müllerian ducts. Testosterone, produced by Leydig cells, promotes the development of 
Wolffian duct derivatives and masculinization of the external male genitalia. Finally, 
insulin-like 3 (Insl3) mediates transabdominal testicular descent into the scrotum [118]. The 
action of LH and production of testosterone start simultaneously in the rat testis on fetal day 
15.5 [119]. In females, differentiation occurs when the absence of AMH allows development 
of Müllerian structures. The lack of androgens permits degeneration of Wolffian ducts, and 
the absence of Insl3 maintains the gonads in the abdomen. In the ovary, the responsiveness 
to LH appears postnatally at the end of the first week of life [120] concomitantly with the 
onset of steroidogenesis [121]. Functional FSH receptors can be detected some days earlier in 
the perinatal rat ovary, at the age of 4–5 days [122]. 
Steroid hormones play a crucial role in fetal gonadal development and ovarian cell 
wellbeing. Estrogen action is needed for normal ovarian development, follicle survival and 
the regulation of female reproduction. The role of estrogens in female sexual development 
has been demonstrated in many studies utilizing mice lacking functional estrogen receptors 
or estrogen-converting enzymes [123, 124]. However, the developmental role of estrogens in 
human fetal ovaries is not well known. In contrast, testicular hormones are crucial for 
testicular formation and function, i.e. induction and maintenance of the male phenotype at 
all stages of development. 
In humans ovarian development starts at around the 5th week of gestation, when primordial 
germ cells migrate into the undifferentiated gonad. Thereafter, the germ cells undergo 
multiple mitotic divisions, and the number of oogonia reaches its peak by the 20th week of 
development. At this time about 7–8 million germ cells are present in the ovary [125]. 
Simultaneously with mitotic divisions, starting around the fetal age of 11–12 weeks, 
primordial germ cells begin to enter meiosis [126]. After the 10th week of gestation granulosa 
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cell precursors start to form, and at 24 weeks of development almost all oocytes are 
enveloped in a primordial follicle structure [127]. The human fetus is exposed to high 
concentrations of maternal and placental estrogens, and estrogens are produced in several 
fetal tissues [128, 129]. However, minimal amounts of fetal circulating estrogens are 
produced in the fetal ovarian follicles [109].  
In the human male at 7 weeks of gestation, the presence of germ cells in the embryonic 
gonadal ridge and of coelomic epithelial cells that give rise to Sertoli cells was observed. 
This was followed by the appearance of Sertoli cells in the testicular tubules and of Leydig 
cells at 9 weeks, and also by the appearance of vascular endothelial cells and peritubular 
myoid cells at 12 weeks [130]. The production of testosterone peaks at around 11 or 12 to 14 
weeks of gestation, as determined by measurements in the testis and fetal blood [131]. 
Between weeks 12 and 20, serum testosterone levels in the male fetus are from 3- to 8-fold 
higher than in the female [132]. 
3. Programming 
During development, there are critical periods in the course of which a system or an organ 
has to mature. The critical periods are defined by the epochs of rapid cell division within an 
organ, and different organs develop at different rates and different times. At these critical 
periods organs are especially vulnerable to challenges such as decreased oxygenation, 
nutrient supply, and altered hormone exposure. If adverse conditions are experienced in the 
window of vulnerability, then the trajectory of development of the responding organ may 
be changed in ways that result in persistent malfunction. The concepts of “nutritional 
programming”, “fetal programming”, “fetal origins of adult disease”, “developmental 
origins of health and disease”, “developmental induction”, and “developmental 
programming” [26, 133-135] imply that some stimulus or an insult at these critical, restricted 
periods in development has long-lasting consequences, setting in train a series of events that 
culminate in the adult onset of disordered function, while the same environmental stimulus 
outside that critical period induces only reversible changes. The concept evolved from 
human epidemiological studies that have shown that impaired intrauterine growth is 
associated with an increased incidence of metabolic, cardiovascular and other diseases in 
later life. Low birth weight, in particular, has been linked to hypertension, glucose 
intolerance, insulin resistance, type 2 diabetes, dyslipidaemia, obesity and reproductive 
disorders in the adult (Figure 1) [133]. The Dutch famine, a unique “natural experiment” 
with a well-defined period of food shortage in an otherwise well-nourished population, has 
shown that maternal undernutrition during gestation compromises health in later life, and 
that these long-term effects depend on its timing during gestation [136]. Intrauterine growth 
retardation (IUGR) and/or delays in attaining motor, verbal and social skills were recorded 
in the offspring of mothers exposed to the influence of a large variety of ”stresses” such as 
loud, unanticipated noise (as experienced by people living under the flight paths of busy 
airports) and living in a country preparing for and ultimately going to war (e.g. the six-day 
Israeli war) [137]. 




Figure 1. Maternal undernutrition or stress increase maternal glucocoticoid levels and decrease the rate 
of their inactivation by 11ß-HSD2 in the placenta that results in fetal glucocorticoid overexposure. The 
synthetic glucocorticoids pass through the enzymatic placental barrier and reach the fetal circulation. 
Consequences of fetal glucocorticoid overexposure are growth retardation and programming of 
endocrine axes with long-term effects. HPA-hypothalamic-pituitary-adrenal axis; GC-glucocorticoids; 
synGC-synthetic glucocorticoids; 11ß-HSD2-11ß-hydroxysteroid dehydrogenase type 2; SA-
somatotropic axis; HPT-hypothalamic-pituitary-thyroid axis; EP-endocrine pancreas; HPG- 
hypothalamic-pituitary-gonadal axis.      
The concept of programming has been tested experimentally in numerous species using a 
wide range of experimental approaches to impair fetal growth. Some of the most commonly 
used experimental models are maternal undernutrition (calorie restriction, protein 
deprivation, iron deficiency), placental insufficiency and exposure to glucocorticoids that 
includes maternal stress, maternal treatment with synthetic glucocorticoids and inhibition of 
placental 11ß-hydroxysteroid dehydrogenase (11β-HSD2) (Figure 1) [138].  
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Majority of these experimental models ultimately result in fetal glucocorticoid 
overexposure, since they mediate the programming effects of nutritional and other 
environmental challenges during pregnancy [139]. Maternal low-protein diet and placental 
11β-HSD2 deficiency cause fetal growth restriction via distinct pathways but with a 
common component: overexposure of fetoplacental tissues to glucocorticoids. Whatever the 
source, glucocorticoids play an important role in the regulation of fetal growth, and through 
this in developmental programming [140]. Glucocorticoids are growth inhibitory and affect 
development of all the tissues and organ systems that are at increased risk of adult 
pathophysiology when fetal growth is impaired [11]. Glucocorticoids signal adverse 
intrauterine conditions and adapt fetal development to ensure the maximum chances of 
survival both in utero and at birth. They act at cellular and molecular levels to induce 
changes in tissue growth and differentiation by direct and indirect mechanisms. At the 
cellular level, glucocorticoid exposure in utero alters receptors, enzymes, ion channels and 
transporters in a wide range of different cell types during late gestation. They also change 
the expression of various growth factors, cytoarchitectural proteins, binding proteins and 
components of the intracellular signaling pathways [139]. These changes will influence the 
basal functioning of the cell and its responses to endocrine, metabolic and other stimuli, 
with consequences for its size, proliferation rate and terminal differentiation. In addition to 
these direct effects, glucocorticoids can act indirectly on tissue proliferation and 
differentiation through changes in the cellular secretion of proteins, hormones, growth 
factors and metabolites [139]. 
Another major mechanism by which glucocorticoids act on physiological systems is through 
changes in hormone bioavailability. They alter the production and secretion by the placenta 
and fetal endocrine glands of a number of hormones, such as estrogen, insulin, gastrin, 
neuropeptide Y, angiotensin II, T3, noradrenaline and adrenaline. They also regulate 
hormone receptor densities and the activities of several enzymes involved in activating and 
inactivating hormones in the fetal tissues. One of the recently proposed mechanisms of 
programming, with particular emphasis on glucocorticoids, is epigenetic programming. 
Glucocorticoids act as epigenetic signals that allow transgenerational transmission of non-
genomic factors important in developing the optimal phenotype for survival to reproductive 
age [141]. The consequences of fetal overexposure to either endogenous or exogenous 
glucocorticoids lead to hypertension, glucose intolerance, insulin resistance, and 
abnormalities in the HPA function after birth [142].  
3.1. Placental 11ß-hydroxysteroid dehydrogenase 2 (11ß-HSD2)  
Transcriptional activation of GR is known to be determined by intracellular glucocorticoid 
availability that is regulated by two distinct isoforms of the enzyme 11ß-HSD. These 
enzymes control the first critical step for GR activation and target gene expression, while the 
process has been termed pre-receptor ligand control [2]. 11ß-HSD1 is NADPH-dependent 
with reductase activity, converting cortisone to the bioactive cortisol in the human, and 11-
dehydrocorticosterone to corticosterone in the rat. 11ß-HSD2 is NAD-dependent and 
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catalyzes the rapid metabolism of cortisol and corticosterone to inactive 11-keto forms, 
cortisone and 11-dehydrocorticosterone, respectively [143]. These enzyme systems function 
in most fetal gucocorticoid sensitive tissues modulating ligand access to GR. This is 
especially important for mineralocorticoid sensitive tissues. In the developing kidney, for 
example, in the presence of 11ß-HSD2, cortisol was efficiently metabolised to inert cortisone, 
which does not bind to receptors allowing aldosterone action. As a consequence, sodium 
retention, potassium loss and hypertension are prevented [5]. 
11ß-HSD2 is highly expressed in the placenta, in the syncytiotrophoblast in humans, and in 
the labyrinthine zone in rodents, i.e. at the interface between maternal and fetal circulations. 
Besides the mentioned function, it has an additional role in the placenta: it selectively 
regulates passage of glucocorticoids from the mother to the fetus, since highly lipophilic 
glucocorticoid molecules are able to pass freely across the placenta [144, 145]. As 
glucocorticoid levels are significantly lower in the fetus than in the mother, the 11ß-HSD2 
placental enzymatic barrier prevents most of the maternal glucocorticoids from reaching the 
fetus, protecting the very sensitive fetal tissues from high glucocortivoid levels during 
development. Although 11ß-HSD2 limits fetal exposure to maternal glucocorticoids, a 
certain amount avoids enzymatic inactivation and reaches the fetus [146]. 11ß-HSD2 
maintains a gradient of glucocorticoids from the maternal to the fetal circulation, although 
its magnitude varies between species. There is a positive correlation between the materno-
fetal gradient and the activity of placental 11ß-HSD2 [139].    
Reduced 11ß-HSD2 placental activity results in higher levels of glucocorticoids reaching the 
fetus, which induces growth retardation and program later disease susceptibility (Figure 1). 
In rats the lowest placental 11ß-HSD2 activity caused the highest fetal exposure to maternal 
glucocorticoids is seen in the smallest fetuses with the largest placenta [146]. In addition, 
low levels of 11ß-HSD2 placental activity decrease birth weight in humans, and can lead to 
adult hypertension [143]. Furthermore, in 11ß-HSD2 knockout mice fetal weight is 
significantly reduced in relation to wild type controls, as a consequence, not only of the 
increased fetal exposure to maternal glucocorticoids, but also altered placental function, i.e. 
decreased transport of nutrients. Thus, absence of 11β-HSD2 compromises not only fetal but 
also placental growth, function and morphology, representing an additional mechanism of 
fetal programming [147]. Since maternal glucocorticoid levels are significantly higher then 
those in the fetus, even modest perturbations of the placental 11β-HSD2 levels or activity 
can have a profound impact on fetal glucocorticoid exposure [148]. Inhibition of 11β-HSD2 
activity by the application of carbenoxolone to gravid females, a potent inhibitor of 11β-
HSD2, reduces birth weight in rats and elevates blood pressure in the adult rat offspring. 
These effects require the presence of maternal adrenal products, since carbenoxolone given 
to adrenalectomized pregnant rats had no effect on birth weight or blood pressure [149].  
Placental 11ß-HSD2 can be avoided by the application of synthetic glucocorticoids. It has 
been demonstrated that treatment of pregnant rats with dexamethasone and betamethasone, 
synthetic glucocorticoids that are poorly metabolized by the enzyme, results in reduced 
birth weight, higher activity of the HPA axis and elevated blood pressure in the adult 
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offspring (Figure 1) [143]. Synthetic glucocorticoids have been shown to up-regulate the 
activity of 11ß-HSD2, and, hence, amplify the placental barrier for physiological 
glucocorticoids [150]. 
It can be concluded that fetuses are protected from environmental perturbations by an 
enzymatic placental barrier that, by regulating fetal exposure to maternal glucocorticoids, 
crucially determines foeto-placental growth. Its deficiency causes programming effects in 
the offspring.  
3.2. Stress during pregnancy and maternal undernutrition 
Exposure to stress during pregnancy has been associated with offspring behavior, 
morphology, physiology, and immunology [151]. Although the mechanisms by which 
stress during pregnancy can influence the development of the offspring are not entirely 
known, elevation of the maternal glucocorticoid levels after stress exposure could be the 
first step in early life programming that predisposes individuals to several illnesses and 
psychiatric disorders. Maternal exposure to alcohol, repeated restraint stress, electric tail 
shocks, and undernutrition during pregnancy induced a corticosterone increase [152, 153]. 
In the offspring of these mothers growth retardation with altered function of the HPA axis 
and glucocorticoid responses under stress challenge, hyperglycemia and other 
dysfunctions related to type 2 diabetes, as well as hypertension were established (Figure 
1) [14, 15, 153].   
Adrenalectomy, as a blockade of the maternal stress-induced corticosterone secretion, 
suppresses the changes established in the offspring of prenatally stressed dams. The 
effects of repeated restraint stress during pregnancy on the offspring HPA axis activity 
and hippocampal mineralocorticoid receptor (MR) level are suppressed by 
adrenalectomy, while the administration of corticosterone to adrenalectomised mothers 
reinstates the effects induced by prenatal stress [153]. Furthermore, a pharmacological 
blockade of the maternal glucocorticoid synthesis with metyrapone also prevented 
hypertension, which is induced by fetal exposure to maternal low-protein diet [154]. 
Adrenalectomy carried out during pregnancy (without stress exposure), although it 
causes the opposite result in relation to stress exposure due to circulating corticosterone 
levels, also affects offspring development. Maternal adrenalectomy performed during 
gestation results in a compensatory increase in fetal corticosterone levels [152], decreases 
body weight in both male and female offspring, while the HPA axis shows a sex-specific 
pattern of vulnerability. In females, a dramatic increase in hypothalamic CRH and GR 
mRNA levels was established on day 14 [155]. All this together points out that  
highly regulated maternal glucocorticoids are indispensable during normal fetal 
development.   
Various types of stress applied during gestation cause a broad spectrum of effects in the 
offspring at any age. Effects of prenatal stress caused by the restraining of pregnant rats 
influence the development of fetal hypothalamic PVN neurons in a duration-dependent 
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manner. Long-lasting stress causes neurotoxic changes of the fetal PVN neurons, including 
CRH neurons that showed significantly shorter total length of the neuronal processes and an 
increased number of apoptotic cells. On the contrary, short-lasting stress facilitates the 
development of these fetal PVN neurons that showed enhanced CRH messenger RNA 
expression, while the varicosities of CRH-containing axons at the median eminence revealed 
more mature morphology. A greater degree of neuronal differentiation, as manifested by an 
increase in both the number of branch points and the total length of the processes from the 
cell body, was also demonstrated [156]. 
Chronic maternal restraint stress during late gestation decreases placental 11β-HSD2 
expression and activity, and reduces body weight in rat fetuses at term. These alterations 
were associated with reduced pancreatic β-cell mass, growth hormone level, and decreased 
glucose concentration in fetal plasma [18]. Other results established hyperglycaemia, 
glucose intolerance and decreased basal leptin levels in prenatally stressed aged male rats as 
dysfunctions related to type 2 diabetes mellitus [15]. These data suggest that maternal stress 
and later dysfunctions such as type 2 diabetes could be linked to the restricted fetal growth 
and the adverse glucocorticoid environment in utero as the consequences of decreased 
placental 11β-HSD2 expression.  
Observations from animal and human studies have linked maternal nutritional status and 
fetal growth retardation with the programming of hypertension and coronary heart disease 
in later life [27]. In the ewe, undernutrition in early pregnancy leads to placental 
enlargements, as adaptation to extract more nutrients. There is a correlation between 
placental weight and systolic blood pressure in adults that tends to rise as placental weight 
increases [157]. Mild protein restriction during pregnancy attenuates placental 11β-HSD2 
expression which leads to overexposure of the fetus to maternal glucocorticoids (Figure 1) 
[14, 143]. Intrauterine growth retardation and disturbed development of the HPA axis 
appear as an outcome [15]. In addition, in the adult offspring subjected to maternal 
undernutrition during pregnancy persistently elevated expression of GR and decreased 
expression of 11β-HSD2 in the kidney, liver and brain mediated tissue-specific increases in 
glucocorticoid action. These changes represent potentially important mechanisms 
contributing to the programming of hypertension in utero [158].    
As presented, it has so far been established that certain types of stress affect the reduction 
of placental 11β-HSD2 expression in rats, suggesting that the fetus and placenta are 
exposed to excessive amounts of glucocorticoids. Thus, deficiency of the placental barrier 
to maternal glucocorticoids may represent a common pathway between the maternal 
environment and feto-placental programming of later disease [12, 18]. Secondly, 
disturbances in placental growth and function, as a consequence of maternal stress 
exposure, decrease fetal nutrient supply and may further contribute to suboptimal fetal 
growth [14, 145]. Both changes, i.e. the reduced maternal glucocorticoid inactivation and 
decreased nutritional supply reflect on the HPA axis activity in fetuses and offspring, 
although the HPA axis response is differentially affected by the gestational stress 
procedure (Figure 1) [151]. Thus, the fetal HPA axis is a possible primary target and is 
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intricately involved in early life disturbance caused by maternal stress exposure with far-
reaching physiological consequences. 
3.3. Antenatal glucocorticoid therapy       
Because glucocorticoids have potent influence on maturation of fetal lung and other 
tissues they have been used for more than 40 years in human pregnancies at risk of 
preterm delivery. Use of antenatal corticosteroid therapy reduced the complications 
associated with preterm delivery such as neonatal respiratory distress syndrome (RSD), 
periventricular hemorrhage, necrotizing enterocolitis and, most importantly, neonatal 
mortality [159]. According to the National Institute of Health [160] all fetuses between the 
24th and 34th week of gestation at risk of preterm delivery should be considered as 
candidates for the beneficial effects of antenatal glucocorticoid treatment. The 
recommended treatment consists of two doses of 12 mg betamethasone given 24 h apart, 
or alternative regimen of four doses of 6 mg dexamethasone given 12 h apart [161]. 
However, antenatal glucocorticoid therapy may produce growth retardation, affective 
and cognitive disturbances as well as other disorders in children and adults [162], thus the 
question of the relative risk and benefit of repetitive courses of prenatal glucocorticoid 
administration is still open (Figure 1).      
Furthermore, the effects of prenatal glucocorticoid administration in cases of congenital 
adrenal hyperplasia (CAH) that must begin early in the first trimester to be effective in 
preventing female genital ambiguity are not completely known. CAH is an inherited 
disease in which a disordered steroidogenic enzyme P450C21 diverts adrenal steroid 
synthesis away from cortisol toward androgen. As a consequence girls are masculinized, 
because the adrenal glands secrete large amounts of androgens during prenatal 
development. Dexamethasone treatment should be introduced very early in pregnancy, 
before the seventh week of gestation, with the aim to increase fetal glucocorticoid 
concentrations, thus suppressing the elevated ACTH level that drives adrenal androgen 
production [146, 163]. 
In obstetric practice different synthetic glucocorticoids are used: dexamethasone, 
betamethasone, or prednisolone. Synthetic glucocorticoids are slightly different from their 
endogenous equivalents in chemical structure. Dexamethasone and bethamethasone both 
have the additional 9α-fluoro groups, and 16β- or 16α-methyl groups, respectively [164]. 
Prednisolone differs from cortisol by a 1-dehydro configuration (Figure 2). The choice of 
the concrete drug use will depend on its biological half-life, which represents the time that 
passes until one half of the initial drug concentration has disappeared from the blood [165]. 
Physiological and synthetic glucocorticoids have been divided into short-, medium- and 
long-acting substances dependent on the duration of measurable biological half-life [165]. 
Cortisol belongs to the short-acting category with the biological half-life of 8–12 h, 
prednisolone belongs to the medium-acting category with the half-life of 12–36 h, while 
dexamethasone and betamethasone have long-acting properties, ranging between 36 and 54 
h [165].   
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Figure 2. The structural formulas of natural (cortisol, cortocosterone) and synthetic glucocorticoids. 
The biological activity of glucocorticoids is partly determined by the rate and selectivity of 
protein binding, because only the unbound glucocorticoids fraction is biologically active. 
Gayrard et al. [166] have found that the plasma free cortisol concentrations (6% to 14%), 
corticosteroid-binding globulin (CBG)-bound (67% to 87%) and albumin-bound (7% to 19%) 
concentrations are similar within species. Cortisol binding decreases as its concentration 
increases [167]. In human plasma, betamethasone and dexamethasone bind predominantly 
to albumin, which has high capacity but low affinity for ligating, while both steroids bind 
only marginally to CBG [167]. Dexamethasone displays higher protein affinity than 
betamethasone. The potency of glucocorticoids in a biological system also depends on its 
affinity for its receptor. Genomic potency of betamethasone was reported to be moderately 
higher than that of dexamethasone, while both steroids have a 25-fold higher affinity to the 
GR than cortisol [168]. 
4. Programming of endocrine axes 
4.1. Programming of the fetal hypothalamic-pituitary-adrenal axis  
The HPA axis is particularly sensitive to glucocorticoid levels. Fetal exposure to excessive 
glucocorticoids, natural or synthetic, can occur via a number of mechanisms including 
maternal stress, undernutrition as well as maternal antenatal treatment. As previously 
noted, synthetic glucocorticoids such as dexamethasone and betamethasone pass easily 
through the placental barrier avoiding the placental enzyme 11β-HSD2 [7], while maternal 
stress and undernutrition affect the same enzyme, resulting in increased fetal exposure to 
maternal glucocorticoids [18]. As the increased fetal exposure to glucocorticoids occurs 
during a critical period of the HPA axis development, when its control is just setting up, 
permanent alterations in the basal and stress induced HPA axis activity and regulation 
occur in the offspring, and sustain throughout life. Crucial changes that underlie the 
programming of the HPA axis will be presented below. Additionally, disturbances of the 
 
Prenatal Glucocorticoids: Short-Term Benefits and Long-Term Risks 357 
complex maturational process such as HPA axis development that have far-reaching 
immediate and delayed physiological effects will be discussed later.     
The hippocampus represents a major inhibitory input to the HPA axis function. This is the 
point where glucocorticoid feedback, via GR an MR in the hippocampus and GR in the 
hypothalamic PVN and anterior pituitary, inhibits further HPA activity [169]. Thus, the 
balance between GR and MR in the hippocampus is an important factor in determining the 
HPA axis feedback sensitivity. Prenatal dexamethasone exposure alters GR and MR 
expression in the developing limbic system of guinea pig fetuses in both a region-specific 
and a sex-specific manner. After a single dexamethasone dose, female fetuses exhibited a 
significant increase in MR and GR mRNA levels in the CA1 and CA2 regions of the 
hippocampus and MR mRNA in the dentate gyrus [170]. Other results showed that multiple 
dexamethasone administration during pregnancy led to a marked increase in hippocampal 
GR and MR mRNA levels in male fetuses [171]. In mice, a single course of dexamethasone 
transiently reduced MR mRNA expression in the fetal hippocampus [172]. In addition, 
prenatal stress, or dexamethasone exposure are implicated in the development of rat 
hippocampal GR and MR in the offspring. In rat offspring exposed to glucocorticoid excess 
during late pregnancy permanently attenuated GR and MR mRNA expression in specific 
hippocampal regions reduced sensitivity to glucocorticoids [173]. The administration of 
betamethasone to pregnant sheep resulted in significant increases in MR and 11-βHSD2 
gene expression in adult animals, reflecting a possible role for the locally produced 
glucocorticoids within the hippocampus, and the potential for long term alterations in HPA 
function [20].  
At the level of the hypothalamic PVN, significantly decreased amounts of CRH mRNA were 
seen in male fetuses and female offspring after treatment of guinea pig mothers with 
dexamethasone or betamethasone, supporting the idea that synthetic glucocorticoids enter 
the fetal brain and inhibit central drive to the fetal HPA axis [171]. In addition, it has been 
shown that prenatal dexamethasone treatment induces a clear delay in increment of CRH in 
the external zone of the median eminence [174]. Morphometric analyses of rat PVN 
neurosecretory cells at eight distinct subdivisions indicate that dexamethasone given to 
pregnant dams causes significant changes in PVN neurosecretory cells in 20-day-old fetuses 
as well as in neonatal offspring. Significantly decreased neurosecretory cell nuclei volume 
and number in PVN, due to decreased proliferative activity, were found at the levels were 
parvocellular neurons are present, i.e. where CRH neurons are dominant [175, 176]. On the 
other hand, removal of maternal adrenals at day 16 of gestation significantly affected the 
size of neurosecretory cells in different subgroups of fetal PVN. These effects persisted 
during the neonatal period [177], confirming that prenatal glucocorticoid exposure alters the 
development and function of prenatal and neonatal PVN.  
Prenatal glucocorticoid application alters the monoaminergic transmitter systems involved 
in the regulation of GR expression in the brain. Significant differences in the turnovers of 
serotonin, dopamine and noradrenaline contents between the weeks 3 and 14 of life were 
found in a wide area in the rat brain [54]. Thus, developmental alterations of 
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monoaminergic neurons, that represent major modulators of the HPA axis function, 
influence endocrine response in the adult offspring. The data suggest that key targets for 
programming include GR gene expression and the CRH system [178]. 
Antenatal treatment with synthetic glucocorticoids affects pituitary development and the 
differentiation of hormone-producing cell types during the fetal period as well as after birth. 
A significant reduction in fetal ACTH cell volume and number was demonstrated in 19 and 
21-day-old fetuses after multiple prenatal dexamethasone administration (Figure 3) [38, 42]. 
Dexamethasone decreased the rate of division of both immature cells and the existing fetal 
ACTH in the period when its proliferation was most intensive, on day 19 of fetal 
development [179], thus leaving long lasting consequences. Multiple dexamethasone 
exposure during pregnancy affects the ultrastructure of ACTH cells, which in the Golgi 
complex show much lower presence of specific granules as well as dilation of the 
endoplasmatic reticulum [180]. Decreased morphometric parameters of the ACTH cells and 
their changed ultrastructure resulted in significantly reduced plasma ACTH levels in fetuses 
and neonatal offspring after multiple dexamethasone administration during pregnancy [180, 
181]. On the contrary, a single dose of dexamethasone, given to pregnant rats on day 16 of 
gestation, suppressed the synthetic activity of fetal ACTH cells, but in the early neonatal 
period this suppression was followed by stimulation of ACTH secretion and increased 
circulating ACTH levels [182]. Other results showed that following antenatal exposure to 
synthetic glucocorticoids in juvenile males POMC mRNA and CRH receptor mRNA on the 
pituitary level were increased [183].     
 
 
Figure 3. a) Intensive immunopositivity of ACTH cells located near the capillary network is 
characteristic for 21-day-old fetus. b) Decreased size, immunopositivity and number of ACTH cells in 
21-day-old fetuses after maternal dexamethasone administration. Bar - 25 m. 
 
Prenatal Glucocorticoids: Short-Term Benefits and Long-Term Risks 359 
After maternal glucocorticoid exposure the absence of peaks in ACTH blood concentration 
in near term (19-day-old) fetuses reduces ACTH-trophic support and reflects on the adrenal 
glands structure and functional activity [42]. Administration of a single or multiple 
dexamethasone dose to pregnant rats induced a significant decrease in adrenal glands 
weight, volume of whole adrenal glands, as well as average volume and total number of 
cells in near term fetuses and neonatal rat offspring, a consequence of the decreased 
proliferative activity of adrenocortical cells [45, 46]. Interestingly, in 19-day-old fetuses the 
proliferative activity of adrenocortical cells that is most intensive in the outer portion of the 
fetal adrenal glands is markedly reduced in ZG. The proliferation rate of adrenocortical cells 
in IZ was not affected by prenatal dexamethasone application [42], suggesting that different 
sensitivity and/or responses of the proliferating cells in ZG and the outer portion of IZ to 
external stimuli could be a possible mechanism for the formation and maintenance of the 
zonal structure of the adrenal cortex [184].  
In the rat adrenal glands of fetuses and pups of dexamethasone treated dams, during during 
the early neonatal period adrenocortical cells in various stages of degeneration were 
abundant, especially near the central part of the gland where zona reticularis (ZR) begins to 
differentiate. Resorption zones with lymphocytic infiltrations and presence of macrophages 




Figure 4. a) Zona glomerulosa (ZG) with numerous dividing cells (→), inner zone (IZ) with 
lymphocytes (black arrowheads), cellular interspaces, and centrally positioned group of chromoblasts 
(CH) are seen in adrenal gland of 21-day-old fetus. b) Decreased number of proliferating cells (→) in the 
adrenal gland of 21-day-old fetuses from gravid females treated with dexamethasone. Infiltration of 
lymphocytes (black arrowheads) and giant cells (white arrowheads) are indications of intensive tissue 
remodeling. Bar - 100 m. 
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structure is affected by prenatal glucocorticoid exposure (Figure 4) [45, 46]. In the juvenile 
period, decreased expression of steroidogenic enzyme CYP17 after antenatal exposure to 
synthetic glucocorticoids has been established, reflecting the persistence of the adrenal 
glands functional changes [183]. 
The influence of a single dexamethasone treatment given to gravid females resulted in  
the decreased volume of adrenal medulla and the number of chromaffin cells that persisted 
during the fetal and neonatal period. Decreased proliferation of chromaffin cells during  
the fetal and early neonatal period was followed by significantly higher values in relation to 
controls during the second neonatal week, indicating the capacity of the adrenal  
gland medulla to recover [185]. Multiple dexamethasone doses applied during pregnancy 
exert a more potent inhibitory effect. A reduced number of chromaffin cells and significantly 
decreased adrenaline content in the adrenals were seen in 14-day-old neonatal  
offspring [181].  
As pointed out, the consequences of fetal glucocorticoid exposure occur at the level  
of central regulation, pituitary ACTH cells and the adrenal gland, causing programming 
effects on HPA axis function in later life. In offspring HPA axis activity may be changed  
in different directions under basal conditions and after stress challenge [186].  
Permanently elevated basal plasma glucocorticoid levels [178, 187], greater glucocorticoid 
response to stress [54] as well as blunted HPA axis response to stress [183] have been 
established in offspring following antenatal exposure to synthetic glucocorticoids. In 
addition, antenatal glucocorticoid treatment programs HPA function in the adult offspring 
in a sex-specific manner [188]. Programming of the fetal HPA axis, although it could have 
had an adverse postnatal outcome, actually demonstrated the amazing plasticity of the HPA 
axis.  
Exposure to stress or glucocorticoids, exogenous or endogenous, causes fetal growth 
retardation and low birth weight in parallel with deregulation of the HPA axis during the 
life cycle [139]. Additionally, there is a correlation between the natural variation in body 
weight and the HPA axis function in offspring. In adult pigs that were low-weight at birth 
and remained small after birth altered HPA axis function has been recorded in later life, i.e. 
elevated adrenal responsiveness to insulin-induced hypoglycaemia [189]. Thus, it can be 
concluded that growth retardation and programming of the HPA axis are two mutually 
dependent processes that actually represent the modality by which prenatal environment 
influences adult stress-related diseases (Figure 1).  
It has been shown that in rodents, effects of programming can be induced by insults even 
in neonatal period of life. One of the striking characteristics of the HPA axis is the stress 
hypo-responsive period during the first 2 weeks of life for species that are immature at 
birth, such as rats and mice. During the stress hypo-responsive period there is low basal 
corticosterone secretion and the inability to increase corticosterone in response to mild 
stressors, in order to protect the developing nervous system from glucocorticoid excess. 
Thus, neonatal glucocorticoid exposure and early life experience that activate the HPA 
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axis have programming effects on HPA axis organization and functioning during the life 
cycle. Postnatal handling attenuated HPA response to stress in adult animals. Most likely 
this is an indirect effect, caused by altered maternal behavior which results in increased 
licking and grooming of pups by the dam. It is considered that serotonin plays a crucial 
role in the persistence of the handling effect through increased hippocampal GR levels 
[190]. Similarly, as adults, the offspring of mothers that exhibited more licking and 
grooming of pups during the first 10 days of life showed reduced HPA axis stress 
response due to increased hippocampal GR mRNA expression and decreased levels of 
hypothalamic CRH mRNA [191]. On the other hand, maternal separations during the 
critical periods of hippocampal development can disrupt hippocampal cytoarchitecture 
and neurogenesis in a stable manner, with stress hyper-responsiveness observed in these 
animals as adults [192, 193].  
4.2. Programming of the somatotropic axis  
Programming of the somatotropic axis (GH-IGF axis) is known to be induced by transient 
events in early postnatal life. The best described example is the effect of transient neonatal 
manipulation of sex steroids to permanently alter subsequent GH secretion to resemble the 
pattern of GH secretion of the opposite sex in rodents [194]. Intrauterine programming of 
the somatotropic (GH-IGF) axis is still not fully understood, despite its importance in 
postnatal growth and metabolism. Synthetic activity, storage, and proliferation of rat 
pituitary GH cells, indicated by the significant increase in GH cell immunopositivity, size, 
and number per volume and unit of area, rise markedly from the 19th till the 21st fetal day 
[195]. This corresponds with an increase in plasma corticosterone concentration in near term 
rat fetuses [46]. It has been shown that dexamethasone administered during the last week of 
pregnancy has a maturational effect on pituitary GH cells in rats [196]. Dexamethasone 
induced GHRHR mRNA expression and accumulation in the fetal rat pituitary gland [70] 
and amplified the stimulatory influence of GHRH. As a consequence, dexamethasone 
induced GH cells to synthesize and release more GH, leading to increases in GH cell size 
and immunopositivity (Figure 5) [196]. Corticosterone-induced GH cell differentiation 
involves GH expression in cells not expressing GH mRNA previously [197]. Moreover, 
dexamethasone can induce GH progenitors to start GH synthesis one day earlier than in 
normal fetuses. In vitro findings suggested that incubation of the pituitary gland with 
dexamethasone for 24 h increased GH mRNA on fetal day 18 to a level nearly identical to 
that in intact 19-day-old fetuses [70]. In humans, low-weight babies have high basal GH and 
low IGF-I concentrations at birth, with an increased GH response to GHRH [198]. These 
altered concentrations are maintained during early childhood and are accompanied by 
changes in the pattern of GH secretion. By early adulthood, urinary GH excretion, which 
reflects GH secretion, is low in men and women with low birth weights, but in old age birth 
weight is unrelated to either urinary GH excretion or the GH secretory profile [198]. Low 
birth weight is associated with decreased IGF-I, IGF-II and IGFBP-3, and elevated levels of 
IGFBP-1 [199]. 
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Figure 5. a) Pituitary GH cells of control 21-day-old fetus. b) Intensive immunostaining of GH cells in 
21-day-old fetuses after maternal dexamethasone treatment. Bar - 25 m. 
In the fetus, IGF-I together with insulin, acts as a signal of nutrient plenty at the cellular 
level and promotes tissue growth in line with substrate availability in the fetus [24]. In 
fetal sheep, concentrations of insulin and IGF-I rise with increasing fetal concentrations of 
glucose over the normal range of values induced by variations in maternal nutritional 
state. The rise in fetal plasma IGF-I probably reflects overspill of IGF-I produced by a 
number of different fetal tissues, since IGF-I is primarily a paracrine growth factor in 
utero. In contrast, the concentrations of cortisol rise as fetal glucose levels decline [200]. 
Fetal undernutrition induced by maternal dietary manipulation, placental insufficiency 
and restriction of uterine blood flow, all reduce the circulating levels and tissue 
expression of IGF-I [200]. Glucocorticoids affect the expression of Igf1 and Igf2 genes, 
although their effects are tissue and Igf-specific. In fetal sheep, cortisol up- and down-
regulates Igf1 gene expression in the liver and skeletal muscle, respectively, whereas it 
down-regulates Igf2 gene expression in these tissues. These changes in tissue expression 
occur both in response to exogenous cortisol infusion before term, and when fetal cortisol 
levels rise endogenously during the immediate prepartum period [200]. The cortisol-
induced changes in tissue Igf gene expression are also accompanied by decreases in the 
fetal growth rate and, close to term, by a fall in plasma IGF-II levels [77, 201]. Cortisol, 
therefore, appears to initiate the switch from paracrine IGF production in utero to the 
hepatic production of endocrine IGF-I characteristic of the postnatal animal. 
Glucocorticoids may act on Igf gene expression either directly or indirectly, through 
changes in the GH receptor gene expression [79] and/or via other transcription factors or 
cortisol-dependent hormones, such as T3 [202]. This premature transition from IGF-II to 
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IGF-I production has beneficial effects on tissue differentiation, should delivery occur 
before full term. However, if delivery is not stimulated prematurely, the glucocorticoid-
induced switch from the fetal to the adult mode of somatotrophic regulation may lead to 
inappropriate changes in cell proliferation and differentiation in utero with adverse 
sequelae both at birth and much later in life [200]. The reduced axial growth and reduced 
femur and tibia length reported in juvenile rats prenatally exposed to dexamethasone 
could serve as an illustration [203]. Altogether, the long-term consequences of such fetal 
changes in the GH-IGF axis are yet not fully understood in terms of functional adaptation 
or diseases. However, glucocorticoid-induced alterations might appear as potentially 
beneficial for short-term survival in an environment of shortage of nutritional resources. 
After birth, normalization of insulin, IGFs and IGFPs occurs. During this period, when 
suddenly exposed to increased concentrations of insulin and IGF-1, tissues chronically 
depleted of these two hormones during fetal life may counteract the hike by developing 
insulin resistance as a metabolic defense against developing hypoglycemia [204]. 
Therefore, infants with low birth weight who show early and complete growth recovery 
could be at higher risk for the occurrence of the metabolic syndrome in adulthood. 
Indeed, recent results in rats have shown permanent and sexually dimorphic changes in 
the expression of genes involved in the GH-IGF axis in animals that were weaned on to a 
high fat diet [203].  
4.3. Programming of the hypothalamic-pituitary-thyroid axis   
Glucocorticoid milieu strongly influences HPT axis activity during critical developmental 
periods. Prenatal alterations in glucocorticoid levels, caused by the application of synthetic 
glucocorticoids, maternal undernutrition or adrenalectomy, reflect on the fetal, neonatal and 
adult HPT axis structure and function.     
Unbiased estimation of the cell number applying a design-based modern stereological 
approach revealed that maternal dexamethasone treatment significantly decreased pituitary 
TSH cell number in near term fetuses. This result together with the strong immunopositivity 
of TSH cells, and the fact that the decreased number of TSH cells sustains serum TSH 
concentrations at the control level, indicates that glucocorticoids exert a maturation-
promoting effect on fetal TSH cells enhancing TSH synthesis (Figure 6) [205]. In sheep 
fetuses, antenatal glucocorticoid administration induced an increase in the circulating T3 
concentration. Tissue-specific changes in deiodinase enzyme activities show stimulation of 
hepatic D1 activity with consequent increases in hepatic T3 production, as well as decreased 
T3 clearance by suppression of D3 enzymes in the kidney and placenta [206]. In the brain, 
glucocorticoid application stimulated TH activity during a period between gestational day 
20 and neonatal day 12 that largely overlaps with the transient window in time during 
which brain development is TH sensitive [207]. On the contrary, maternal undernutrition 
during the gestational period results in lower serum T3 and higher serum reverse T3 
concentrations in neonatal pups [208].   
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Figure 6. a) Numerous TSH cells characteristic for pituitary of 21-day-old fetus. b) Decreased number of 
TSH cells, with intense immunopositivity was observed in 21-day-old fetuses after maternal 
dexamethasone administration. Bar - 25 m. 
Alteration of the glucocorticoid milieu caused by maternal adrenalectomy influences HPT 
axis functioning in adult offspring. Decreased hypothalamic TRH mRNA levels and 
increased plasma TSH levels recorded in both male and female adult offspring of 
adrenalectomized dams were reversed by the administration of corticosterone to the 
pregnant adrenalectomized dam. The decreased plasma T3 concentrations in female 
offspring, which were reversed by the administration of higher levels of corticosterone to 
the adrenalectomized pregnant rats, suggest that the adult HPT axis responded to variations 
in maternal glucocorticoid milieu in a sex-specific manner [209].   
Importantly, TH per se are potent programming factors. Fetal and neonatal 
hyperthyroidism or hypothyroidism results in programming of the HPT function. During 
critical periods, TSH secretion is suppressed by an excess of TH, but cannot be increased 
despite the marked lowering of circulating TH caused by perinatal propylthiouracil 
administration. More importantly, perinatal thyroid status "programs" its own future 
reactivity, so that early hypothyroidism results in reduced T4 and T3 levels in adulthood, 
despite normal levels of TSH [210].   
TH influence the accretion, differentiation and metabolism of many tissues and cell types 
during development in a time-dependent manner. The effects of its deficiency during critical 
periods, when the tissues still have some plasticity and are in a higher proliferating and 
differentiating stage, are thus notable, often permanent. Fetal hypothyroidism leads to 
asymmetrical growth retardation, with reduction in muscle mass [211]. Fetal metabolism 
and utilization of oxygen, as well as bone tissue growth were adversely affected by TH 
deficiency in utero [211]. A well known example is that hypothyroidism during the period 
of thyroid-dependent brain development, in fetuses and during infancy, causes permanent 
mental retardation [212]. Thus, the structure and function of TH-dependent tissues, 
determined during critical periods by the striking effects of TH action [139], might be the 
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cause of different (patho)physiological alterations which manifest during the life cycle. The 
potent influence of glucocorticoids on serum TH concentrations and the TH tissue 
bioavailability in the same period represents an important additional cause of the 
programming events recorded in different tissues.  
4.4. Programming of endocrine pancreas 
A number of epidemiological and clinical studies demonstrate an association between low 
birth weight and an increased incidence of metabolic, cardiovascular and other diseases in 
adult life. Adverse intrauterine environment caused by inadequate maternal nutrition status 
[13], poor placental function [17], maternal stress [15] or treatment with synthetic 
glucocorticoids [187] is linked with impaired intrauterine growth and increased rates of 
metabolic diseases such as type 2 diabetes in adulthood.   
The increased fetal glucocorticoid exposure observed during and after suboptimal 
conditions, triggers cell differentiation in many of the tissues, resetting the set points of 
metabolic homeostasis and endocrine axes and in most individual fetal tissues leads to 
weight reduction, restricted fetal growth and decreased birth weight [24]. Glucocorticoids 
therefore switch the cell cycle from tissue accretion to tissue differentiation in preparation 
for delivery. At the same time, glucocorticoids are involved in the programming of the HPA 
axis during critical periods, causing structural and functional changes specified in the above 
section. Alterations in the feedback sensitivity of the fetal HPA axis, as adaptation to 
suboptimal conditions, mostly result in enhanced HPA axis activity postnatally, under basal 
conditions or after stress challenge, with elevated glucocorticoid levels [21]. These changes 
are in close association with the programming of susceptibility in the fetus to develop 
metabolic syndrome in later life. Indeed, hyperactivity of the HPA axis with chronically 
elevated glucocorticoids is positively correlated with the metabolic syndrome, which 
includes a cluster of symptoms such as hyperglycemia, hyperinsulinemia, or insulin 
resistance. Dyslipidemia, hyperleptinemia, raised serum triglycerides, lowered serum high-
density lipoprotein cholesterol, and high blood pressure have also been recorded. All of 
those risk factors are a prelude to the development of diseases such as type 2 diabetes, 
atherosclerosis and cardio-vascular complications [28].  
Suboptimal conditions in utero lead to changes in the endocrine environment which 
influence fetal development so that its nutrient requirements are decreased and a thrifty 
phenotype is produced to maximize its chances for survival. These short-term beneficial 
adaptations may be maladaptive in postnatal life, contributing to poor health outcomes [26]. 
If postnatal nutrient availability is better than predicted, metabolic dysfunctions occur, as 
the organism is not adapted to cope with excessive caloric intake in later life. The association 
of low birth weight with early postnatal catch-up growth, in situations where discrepancies 
between the pre- and postnatal environment are significant, adversely affects body 
composition, producing increased susceptibility to non-insulin dependent type 2 diabetes. 
But if environmental conditions remain unchanged, and the offspring of mothers on a low 
protein diet continue with the low protein diet during lactation, development of the 
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metabolic phenotype is prevented. The “predictive adaptive response” hypothesis proposes 
that the degree of mismatch between the pre- and postnatal environments is a major 
determinant of subsequent disease, and leads to the premise that adult disease arises in utero 
[28, 213].  
The thrifty phenotype is not able to respond to unexpected environmental conditions 
because the changes in metabolic tissues established during critical periods are directed 
towards low nutritional demands. The fetus adapts to an adverse intrauterine milieu 
through changes that permanently affect the pancreas, muscles, adipose tissue, and liver 
structure and function, which are involved in the pathogenesis of obesity and type 2 
diabetes [25]. 
Progressive reduction in insulin-producing β-cell mass is observed in rats with restricted 
fetal growth [214]. There is evidence that prenatal caloric restriction during pregnancy 
causes alteration in pancreatic islet neogenesis by decreasing the β-cell precursor pool [215], 
while maternal protein restriction in rats lowers β-cell proliferation and/or increases 
apoptosis rates in the fetal endocrine pancreas [215, 216]. Permanent reductions in β-cell 
mass and its functional efficiency, although achieved by different mechanisms, result in 
glucose intolerance in adulthood [214]. Nutritional deprivation as severe stress induces a 
rise in both maternal and fetal corticosterone levels, which in turn are responsible for the 
observed effects [217].       
Prenatal stress that induces a restriction in intrauterine growth in aged male rats causes 
hyperglycemia, glucose intolerance, and decreased basal leptin levels. Again, an adverse 
glucocorticoid environment during critical periods might be the underlying mechanism that 
mediates long-lasting disturbances in feeding behavior and dysfunctions related to type 2 
diabetes [15].   
Overexposure to exogenous glucocorticoids during different stages of development reduces 
β-cell mass in the fetal endocrine pancreas: impairment of β-cell commitment is recorded in 
fetuses exposed to glucocortiocoid during the last week of gestation, while glucocorticoids 
treatment throughout gestation lowers β-cell proliferation and impairs islet vascularization 
[218]. Glucocorticoid excess during the last week of gestation leads to lower levels of insulin 
expression in the β-cells of 3-week-old offspring via a mechanism that involves down-
regulation of Pdx-1, the transcription factor that initiates and promotes β-cells development 
[219]. Programming of the functional capacity of pancreatic β-cell mass by adverse 
intrauterine conditions increases susceptibility to type 2 diabetes during adulthood that is 
especially evident if offspring when they are challenged with nutritional abundance. As 
during adulthood the majority of β-cells are formed through proliferation of the existing 
cells [220], smaller β-cell mass in the newborn means fewer β-cells will be available for 
renewal during life, which increases the risk of developing glucose intolerance or diabetes 
[221].  
Impaired insulin action at the major sites of glucose utilization, such as skeletal muscles, 
liver and adipose tissue, further predisposes to a later diabetic state. Excess prenatal 
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glucocorticoid exposure, uteroplacental insufficiency as well as maternal low protein diet 
in the perinatal period prepare skeletal muscle metabolism for poor metabolic conditions 
in later life [22, 25, 213]. These changes include up-regulation of GR expression that 
determines higher muscle glucocorticoid sensitivity, with the promotion of protein 
breakdown and blunted protein synthesis in muscles [222]. Prenatal growth restriction 
caused by adverse intrauterine conditions of different etiology has a long-term influence 
on adiposity. Redistribution of body fat from the periphery to the central or visceral 
deposits that have a relatively higher level of GR expression and are thus more sensitive 
to glucocorticoid action is established in adult rats and sheep prenatally exposed to 
glucocorticoid excess [223-225], contributing to decreased insulin sensitivity and blunted 
glucose intake [2]. Adipocytes from 15-month-old low-protein rat offspring are also 
resistant to the antilipolytic action of insulin and insulin-induced glucose uptake [25]. It 
can be concluded that adverse conditions during critical periods may program adipocyte 
metabolism to give rise to later obesity and type 2 diabetes, especially when challenged 
postnatally with a hypercaloric diet [226]. Suboptimal conditions during fetal 
development program an increased level of liver GR expression that enables much higher 
glucocorticoid impact in diabetic animals [227]. Down-regulation of glucokinase activity 
in parallel with decreased liver glucose uptake, and up-regulation of gluconeogenic 
enzyme activities, notably phosphoenolpyruvate carboxykinase which catalyzes a rate-
limiting step in gluconeogenesis, have been established in rats exposed to excessive 
glucocorticoids in utero [25, 228]. The programming effects established in glucocorticoid 
overexposed fetuses with restricted growth are thus directed toward enhanced glucose 
production and reduced glucose utilization in the liver and other peripheral tissues in 
adulthood, and represent the structural and physiological basis of the development of 
type 2 diabetes [19].    
4.5. Programming of hipothalamic-pituitary-gonadal axis 
Steroid hormone excess during fetal life, including glucocorticoids and sex hormones, is 
well known to induce permanent alterations in the physiology of the adult HPG axis in 
both sexes [229]. The majority of data describing the effects of elevated levels of 
glucocorticoids on the HPG axis and possible mechanisms, come from studies in adults, 
and there are only limited data on fetal effects. It has been known that the HPA axis, 
when activated by stress, exerts an inhibitory effect on the female and male reproductive 
system. Reallocation of resources during the stress response suppresses the reproductive 
axis, which gives higher priority to an individual’s survival rather than the maintenance 
of species. This effect is responsible for the “hypothalamic amenorrhea of stress” in 
females, which is observed in anxiety and depression, malnutrition, eating disorders and 
chronic excessive exercise, and the hypogonadism in Cushing’s syndrome [230]. Stressors 
trigger a rise in glucocorticoids that suppress reproductive functions along the HPG axis 
[3]. Glucocorticoids decrease expression of GnRH mRNA [231] in the hypothalamus, and 
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are associated with alterations in both FSH and LH cells [232, 233]. Glucocorticoids also 
affect gonads directly. It has been reported that dexamethasone inhibits ovarian function 
in immature female rats and the differentiation of granulosa cells by FSH [234]. In the 
testis, elevated levels of glucocorticoids suppress testosterone biosynthesis [3]. 
Additionally, dexamethasone induces apoptosis of tubules and germ cells in adult rat 
testis [235].  
Elevation of maternal glucocorticoids induced by maternal stress, undernutrition or 
exogenously administered dexamethasone or betamethasone, along with IUGR  
cause alterations in HPG axis function in male and female offspring. The major alterations 
reported were related to changed sexual behavior, delayed puberty, and delayed 
development of the gonads. In rats, exposure to prenatal stress demasculinizes  
and feminizes the behavior of the male offspring. When dams are restrained under  
bright light from days 14 to 21 of gestation, the male offspring display reduced  
anogenital distance and lower testis weight at birth compared to controls [18, 236],  
which could predict impaired sexual activity at adulthood [237]. Prenatal treatment  
with glucocorticoids caused the disappearance of sexual dimorphism of aromatase 
activity in the brain preoptic area of rat pups in early postnatal life [238].  
Prenatal bethamethasone treatment diminished the testosterone peak in male pups, a 
peak crucial for brain sexual differentiation. As a consequence, this prenatal  
treatment may have impaired the hypothalamus–pituitary axis, thus reducing production 
of testosterone in adulthood and altering the partner preference and sexual  
behavior [239]. 
It has been reported that maternal protein restriction altered the key components of 
pregnant maternal steroid endocrinology, as well as the endocrinology of the offspring. 
Maternal corticosterone and testosterone levels were elevated, which resulted in an 
increased anogenital distance in males [240].  In females exposed to protein restriction 
during development the onset of puberty was delayed and the cycle length was increased 
[241]. The decrease of LH and slight, but not significant, decrease of FSH levels was 
detected in adult females that experienced maternal protein restriction at some stage of 
development. Together with the increases in testosterone levels at 1 year, this presage 
potential reproductive problems, including changes in the ovarian cycle [241]. Maternal 
protein restriction leads to similar changes in reproductive hormones in the male 
offspring [240], indicating that a major effect of the challenge imposed on the developing 
offspring is to alter hypothalamic–pituitary endocrine function. The reproductive function 
aged more rapidly in females that had been exposed to protein restriction during 
development [241]. Testicular and ovarian growth was drastically retarded, and the onset 
of puberty was delayed in male and female rats prenatally exposed to maternal food 
restriction [242]. In addition, the ovulation rate in adulthood was reduced in female sheep 
that experienced undernutrition during the prenatal period [243]. The suggested main 
mechanism by which maternal calorie restriction induced delay of puberty in the female 
offspring is that decreased function of the kisspeptin system retards the development of 
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reproductive function and the onset of puberty. Hypothalamic levels of Kiss1 mRNA were 
decreased in prenatally undernourished rats, and the replacement of kisspeptin 
normalized the timing of vaginal opening in these females [244]. However, this 
mechanism is not responsible for delaying puberty in dexamethasone-induced IUGR 
females, since the levels of Kiss1 mRNA were not altered [245]. On the other hand, 
alterations of ovarian functions found in dexamethasone-induced IUGR rats, can affect 
sexual maturation [246]. As ovarian weight in the dexamethasone-induced IUGR rats was 
lower than in the controls during the prepubertal period (postnatal day 28), but not on the 
day of vaginal opening, the retardation of ovarian function development might be 
involved in the delayed onset of puberty [245]. Smith and Waddell [247] have shown that 
variations in fetal glucocorticoid exposure across the normal physiological range are 
capable of influencing the timing of subsequent puberty. Puberty was substantially 
delayed by increased exposure to glucocorticoids, which was most clearly evident in 
female offspring. Of particular importance were the observations that increased exposure 
of the fetus to endogenous maternal glucocorticoids (via inhibition of placental 11β-HSD 
by carbenoxolone treatment) delayed puberty in the female offspring, whereas an 
experimental reduction in fetal glucocorticoid exposure (by maternal metyrapone 
treatment) advanced puberty in the male offspring [247].  
When higher multiple doses of dexamethasone were administered to dams between the  
16th and 18th day of gestation, a significant reduction in body weight was recorded in near-
term fetuses that persisted till the peripubertal period of life. The volume of pituitaries of the 
exposed females were also significanly reduced till the peripubertal period. The  
absolute number of both types of gonadotropic cells, obtained by design-based stereological 
methods, was decreased in the pituitaries of exposed females (Figure 7). As the pituitaries, 
the ovaries of exposed females were smaller than that of controls (Figure 8).  
Significant decrease in healthy, but an increase in atretic primordial follicles was observed in 
neonatal period (at 5 days of age) [246]. Alterations in the number of healthy and 
degenerated germinative cells were evident in fetuses as well, and sustained  
till the peripubertal period of life. Since the puberty was delayed in females exposed 
prenatally to dexamethasone, no corpora lutea were seen in their ovaries. In contrast, 3-5 
corpora lutea were present in the ovaries of control females (Figure 8). However, the  
process of folliculogenesis remained unchanged, since the follicles at all stages of 
development seen in the ovaries of control females in the neonatal [246], infantile and 
peripubertal period, were present in the ovaries of females prenatally exposed to high levels 
of glucocorticoids. Therefore, a clear programming effect of dexamethasone was detected in 
the female HPG axis. It has been shown that glucocorticoids mediate changes in the 
dynamic balance between mitosis and apoptosis [248], and may be a mechanism for the 
control of total cell number in developing tissues and organs [249, 250]. This could be one of 
the mechanisms by which glucocorticoid overexposure affects the hypothalamic–pituitary–
ovarian axis.  
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Figure 7. Immunohistochemically stained FSH cells in the pituitaries of control (a-d), and females 
prenatally exposed to dexamethasone (e-h). FSH cells were examined in different periods of life: in 
nearm-term fetal period (a, e), neonatal (b, f), infantile (c, g) and peripubertal period (d, h). In all 
examined periods the number of FSH cells was lower in the pituitaries of dexamethasone exposed 
females compared to controls. Bar - 20 μm. 
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Figure 8. Ovaries of control (a-d), and females prenatally exposed to dexamethasone (e-h). Ovaries 
were examined in different periods of life: in nearm-term fetal period (a, e), neonatal (b, f), infantile (c, 
g) and peripubertal period (d, h) and they were smaller in dexamethasone exposed females. Numerous 
primordial follicles (dashed line) are present in the ovaries of control females, while they were fewer in 
number in the ovaries of dexamethasone exposed rats in all examined periods of life. Bar - 200 μm. In b) 
and f) bar - 20 μm. 
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Maternal bethamethasone administration affected the morphological development of the 
testes in male sheep fetuses, by reducing the length of testicular cords, the amount of 
interstitial tissue and testicular weight. Because interstitial tissue is primarily made up of 
Leydig cells, it is possible that betamethasone altered Leydig cell development. In contrast, 
there was no inhibitory effect on Sertoli cell number. This could be a result of the direct 
influence of the glucocorticoid used, since the presence of glucocorticoid receptor was 
demonstrated in ovine fetal Leydig cells, while the level of glucocorticoid receptor 
expression in Sertoli cells was low [251]. 
Fetal overexposure to glucocrticoids without any doubt has programming effects on the HPG 
axis, and reproduction in later life is thus impaired in both sexes. However, the mechanism of 
HPG programming is yet to be elucidated. The time interval between the exact insult and a 
fully functioning HPG axis is long, and prone to influences and interplay with other endocrine 
axes that are also altered by glucocrticoid overexposure. For example, an impaired 
somatotropic axis negatively affects reproduction. Somatostatin treatment inhibits pituitary 
gonadotropic cells and initial folliculogenesis in the ovaries of infant, peripubertal and adult 
females [252-257]. Polycystic ovary syndrome (PCOS) is of great importance, owing to its 
prevalence in up to 10% of the women population of reproductive age. Besides being 
characterized by perturbed gonadotropin secretion and excess production of androgens, PCOS 
shares a lot of commons with the metabolic syndrome. Metabolic syndrome is also believed to 
be of fetal origin and the result of programming in which glucocorticoids play a crucial role 
[213]. The short-term benefits of glucocorticoid exposure are also difficult to establish due to 
physiological dormancy of the system till puberty. The maturational effect of glucocorticoids is 
evident in the pituitary and in the ovary, since fetal overexposure induces a decreased volume 
of these glands, and of the absolute number of gonadotrops and ovarian somatic and 
germinative cells till puberty (Figure 1).  
5. Conclusion 
Glucocorticoids have a powerful influence on growth, maturation and tissue remodeling 
during fetal development. Their use in human pregnancies at risk of preterm delivery 
reduces neonatal mortality and morbidity. Glucocorticoids are also the key mediators 
between the maternal environment and the fetus, and their levels rise, in the mother and in 
the fetus, when the conditions are suboptimal. They reduce fetal growth, force maturational 
processes and provoke permanent changes in physiological systems in order to adapt the 
fetus to an adverse postnatal environment and ensure the maximum chances of survival at 
birth. These short-term beneficial effects of prenatal glucocorticoids are, at the same time, 
the ones that increase the long-term risks of dysregulation of the metabolic function and 
endocrine axes, including stress response, growth and reproduction. 
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